- Home
- AGEN vs ACET Comparison
AGEN vs ACET Comparison
Compare AGEN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ACET
- Stock Information
- Founded
- AGEN 1994
- ACET 1947
- Country
- AGEN United States
- ACET United States
- Employees
- AGEN N/A
- ACET N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- ACET Health Care
- Exchange
- AGEN Nasdaq
- ACET Nasdaq
- Market Cap
- AGEN 52.6M
- ACET 44.4M
- IPO Year
- AGEN 2000
- ACET N/A
- Fundamental
- Price
- AGEN $2.91
- ACET $0.61
- Analyst Decision
- AGEN Buy
- ACET Buy
- Analyst Count
- AGEN 4
- ACET 6
- Target Price
- AGEN $8.00
- ACET $6.00
- AVG Volume (30 Days)
- AGEN 830.5K
- ACET 566.6K
- Earning Date
- AGEN 05-12-2025
- ACET 05-06-2025
- Dividend Yield
- AGEN N/A
- ACET N/A
- EPS Growth
- AGEN N/A
- ACET N/A
- EPS
- AGEN N/A
- ACET N/A
- Revenue
- AGEN $103,463,000.00
- ACET N/A
- Revenue This Year
- AGEN $4.03
- ACET N/A
- Revenue Next Year
- AGEN $5.57
- ACET N/A
- P/E Ratio
- AGEN N/A
- ACET N/A
- Revenue Growth
- AGEN N/A
- ACET N/A
- 52 Week Low
- AGEN $1.38
- ACET $0.45
- 52 Week High
- AGEN $19.69
- ACET $1.81
- Technical
- Relative Strength Index (RSI)
- AGEN 59.81
- ACET 48.77
- Support Level
- AGEN $2.87
- ACET $0.47
- Resistance Level
- AGEN $3.16
- ACET $0.70
- Average True Range (ATR)
- AGEN 0.35
- ACET 0.06
- MACD
- AGEN 0.02
- ACET 0.00
- Stochastic Oscillator
- AGEN 56.25
- ACET 61.84
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.